These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9209364)

  • 1. The runt protein and its companion PEBP2: a close link between this transcription factor and AML.
    Ito Y
    Leukemia; 1997 Apr; 11 Suppl 3():279-80. PubMed ID: 9209364
    [No Abstract]   [Full Text] [Related]  

  • 2. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
    Meyers S; Lenny N; Sun W; Hiebert SW
    Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
    Zent C; Rowley JD; Nucifora G
    Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional mutagenesis of AML1/RUNX1 and PEBP2 beta/CBF beta define distinct, non-overlapping sites for DNA recognition and heterodimerization by the Runt domain.
    Nagata T; Werner MH
    J Mol Biol; 2001 Apr; 308(2):191-203. PubMed ID: 11327761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha.
    Ogawa E; Inuzuka M; Maruyama M; Satake M; Naito-Fujimoto M; Ito Y; Shigesada K
    Virology; 1993 May; 194(1):314-31. PubMed ID: 8386878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional domains of the t(8;21) fusion protein, AML-1/ETO.
    Lenny N; Meyers S; Hiebert SW
    Oncogene; 1995 Nov; 11(9):1761-9. PubMed ID: 7478604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-binding domain of AML1, expressed in t(8;21) and t(3;21) myeloid leukemias, inhibits PEBP2/CBF DNA-binding but is not sufficient to transform 32D cl3 myeloid cells.
    Britos-Bray M; Sacchi N; Friedman AD
    Leukemia; 1996 Jun; 10(6):984-90. PubMed ID: 8667656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AML1 and Pebp2: the gene for a transcription factor is involved in recurring translocations in human acute myeloid leukemia.
    Rowley JD
    Jpn J Cancer Res; 1994 Dec; 85(12):inside front cover. PubMed ID: 7852178
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression of the Runt domain-encoding PEBP2 alpha genes in T cells during thymic development.
    Satake M; Nomura S; Yamaguchi-Iwai Y; Takahama Y; Hashimoto Y; Niki M; Kitamura Y; Ito Y
    Mol Cell Biol; 1995 Mar; 15(3):1662-70. PubMed ID: 7862157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of MTG8 in leukemogenesis.
    Kozu T; Komori A; Sueoka E; Fujiki H; Kaneko Y; Matsui T; Uehara T; Seino Y; Ishii M
    Leukemia; 1997 Apr; 11 Suppl 3():297-8. PubMed ID: 9209371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AML1 gene in human leukemias: dominant negative effects of the chimeric proteins over wild-type AML1.
    Zhang DE
    Jpn J Cancer Res; 1997 Jun; 88(6):inside front cover. PubMed ID: 9263526
    [No Abstract]   [Full Text] [Related]  

  • 12. Recognition DNA sequence of a novel putative transcription factor, BCL6.
    Kawamata N; Miki T; Ohashi K; Suzuki K; Fukuda T; Hirosawa S; Aoki N
    Biochem Biophys Res Commun; 1994 Oct; 204(1):366-74. PubMed ID: 7945383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials.
    Bae SC; Ogawa E; Maruyama M; Oka H; Satake M; Shigesada K; Jenkins NA; Gilbert DJ; Copeland NG; Ito Y
    Mol Cell Biol; 1994 May; 14(5):3242-52. PubMed ID: 8164679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies.
    Kurokawa M; Tanaka T; Tanaka K; Ogawa S; Mitani K; Yazaki Y; Hirai H
    Oncogene; 1996 Feb; 12(4):883-92. PubMed ID: 8632911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New mechanisms of AML1 gene alteration in hematological malignancies.
    Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
    Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Loss-of-function of AML1/PEBP2 alpha B and leukemogenesis].
    Osato M; Ito Y; Asou N
    Tanpakushitsu Kakusan Koso; 2000 Jan; 45(1):40-7. PubMed ID: 10643334
    [No Abstract]   [Full Text] [Related]  

  • 17. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
    Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
    Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for core binding factor gene rearrangements in acute myeloid leukemia.
    Grimwade D
    Leukemia; 2002 May; 16(5):964-9. PubMed ID: 11986969
    [No Abstract]   [Full Text] [Related]  

  • 20. Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian Runt domain.
    Bae SC; Takahashi E; Zhang YW; Ogawa E; Shigesada K; Namba Y; Satake M; Ito Y
    Gene; 1995 Jul; 159(2):245-8. PubMed ID: 7622058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.